A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Inclusion Criteria

• The participant has well-differentiated or moderately-differentiated, histologically confirmed neuroendocrine carcinoma, including carcinoid of any location and islet cell tumors
• The participant has metastatic disease at the time of study entry
• The participant must have a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, measurable by elevated tumor markers (eg, 24-hour urine 5-HIAA, chromogranin A, adrenocorticotropin hormone (ACTH), gastrin, or other tumor specific biochemical markers), or both
• The participant is age ≥ 18 years
• The participant's tumor has Ki-67 expression ≤ 20%
• The participant is receiving depot octreotide therapy at the time of enrolling into the study
• The participant has received 0 - 2 systemic anticancer regimens in addition to depot octreotide, which may have included chemotherapy, interferon, antiangiogenic therapy, other targeted treatments, or a combination of such treatments
• The participant is no longer a candidate for surgery, embolization, or radiofrequency ablation therapy
• The participant has experienced radiographic, biochemical, and/or scintigraphic disease progression while on a regimen that includes octreotide
• The participant has completed prior chemotherapy and/or radiotherapy with curative intent at least 3 weeks prior to the administration of the first dose of study therapy. Participants that have received palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible
• The participant has a life expectancy of > 3 months
• The participant has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2
• The participant has adequate hematologic function as defined by absolute neutrophil count ≥ 1500/microliters (μL), hemoglobin ≥ 9 gram/deciliter (g/dL), and platelet count ≥100,000/μL
• The participant has adequate hepatic function as defined by a total bilirubin ≤ 1.5 x the upper limit of normal (ULN), and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x the ULN (or ≤ 5 x the ULN in the presence of known liver metastases)
• The participant either has adequate coagulation function as defined by international normalized ratio (INR) ≤ 1.5 and partial thromboplastin time (PTT) no more than 5 seconds above the ULN, or is on a stable dose of anticoagulant
• The participant has adequate renal function as defined by serum creatinine ≤ 1.5 x the institutional ULN or creatinine clearance ≥ 60 milliliter/minute (mL/min) for participants with creatinine levels above the ULN
• The participant has fasting serum glucose < 160 milligram/deciliter (mg/dL) and hemoglobin A1c (HgbA1c)≤ 7. If baseline nonfasting glucose is < 160 mg/dL, fasting glucose measurement is not required
• Because the teratogenicity of cixutumumab is not known, women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
• The participant has the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• The participant has uncontrolled brain or leptomeningeal metastases
• The participant has not recovered to Grade ≤ 1 from adverse events due to agents administered more than 4 weeks prior to study entry (except for alopecia)
• The participant is receiving any other investigational agent(s)
• The participant has received therapeutic radiolabeled somatostatin analogues
• The participant has received more than 2 prior regimens of systemic therapy in the metastatic setting
• The participant has a history of treatment with other agents targeting the IGF receptor
• The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of cixutumumab or to octreotide
• The participant has poorly controlled diabetes mellitus. Participants w